Abstract | OBJECTIVES: METHOD: MDA-MB-453, BT-549, MDA-MB-231 and MDA-MB-468 TNBC cell lines were used for in vitro studies. Protein expressions were assessed by Western blot analysis. Cytostatic effect was examined by MTT assay. Cell cycle and apoptosis were examined by flow cytometry. RESULTS:
Palbociclib showed inhibitory effect in RB-proficient TNBC cells, and enzalutamide inhibited cell viability in AR-positive TNBC cells. Enzalutamide treatment could enhance the palbociclib-induced cytostatic effect in AR-positive/RB-proficient TNBC cells. In addition, palbociclib-mediated G1 arrest in AR-positive/RB-proficient TNBC cells was attenuated by RB knockdown. CONCLUSION: Our study provided a preclinical rationale in selecting patients who might have therapeutic benefit from combining CDK4/6 inhibitors with AR antagonists.
|
Authors | Chun-Yu Liu, Ka-Yi Lau, Chia-Chi Hsu, Ji-Lin Chen, Chia-Han Lee, Tzu-Ting Huang, Yi-Ting Chen, Chun-Teng Huang, Po-Han Lin, Ling-Ming Tseng |
Journal | PloS one
(PLoS One)
Vol. 12
Issue 12
Pg. e0189007
( 2017)
ISSN: 1932-6203 [Electronic] United States |
PMID | 29261702
(Publication Type: Journal Article)
|
Chemical References |
- Benzamides
- Nitriles
- Piperazines
- Pyridines
- Receptors, Androgen
- Retinoblastoma Protein
- Phenylthiohydantoin
- enzalutamide
- palbociclib
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Benzamides
- Cell Line, Tumor
- Drug Screening Assays, Antitumor
- Female
- G1 Phase
(drug effects)
- Humans
- Nitriles
- Phenylthiohydantoin
(analogs & derivatives, analysis)
- Piperazines
(analysis)
- Pyridines
(analysis)
- Receptors, Androgen
(genetics, metabolism)
- Retinoblastoma Protein
(genetics, metabolism)
- Triple Negative Breast Neoplasms
(metabolism, pathology)
|